Gout
Olga Petryna DrPetryna
4 years 11 months ago
@RheumNow #ACR20 Abs L08 Prospective 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat was not associated w/increased risk of death compared w/allopurinol. 222 (7·2%) pts died in the febuxostat group compared to 263 (8·6%) in the allopurinol group
David Liew drdavidliew
4 years 11 months ago
FAST trial: allopurinol vs febuxostat on safety
(for gout pts on allopurinol, with ≥1 CV RF, TTT dosing)
febuxostat non-inferior for CV events
Well, that's a relief.
gout flare similar, good follow-up, colchicine did not influence
out in Lancet today?
#ACR20 ABSTL08 @RheumNow https://t.co/5LeXV5mgu9
NatRevRheumatol NatRevRheumatol
4 years 11 months ago
Results of the FAST trial presented at #ACR20
- Safety study required by the EMA
- Febuxostat non-inferior to allopurinol for any outcomes
- Long-term use of febuxostat is not associated with an increased risk of death
Published in @TheLancet today https://t.co/EvJGPpDCR8
Richard Conway RichardPAConway
4 years 11 months ago
Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovascular events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat @rheumnow #ACR20 Abstr#L08 #ACRbest
Dr. John Cush RheumNow
4 years 11 months ago
FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/FkdDtPB4Oi https://t.co/J9KonQHpT2
What's New in Calcium Pyrophosphate Disease? with Dr. Michael Pillinger
NYU's Dr. Pillinger talks about Dr. Ann Rosenthal's state of the art talk on calcium pyrophosphate disease at ACR 2020.
Who has more comorbidities? Dr. Janet Pope
Dr. Janet Pope reviews abstract #1466 presented at the 2020 ACR annual meeting. Who has more comorbidities: OA, Gout, RA or PsA?
Febuxostat bad for the heart? Not so FAST: Dr. Jeffrey Curtis
Dr. Jeff Curtis from UAB examines the use of Febuxostat (abstract L08) presented at the 2020 ACR annual meeting.
Comorbidities in Gout with Dr. Nicola Dalbeth
Dr. Dalbeth examines abstracts #1466 and #0660 relating to the comorbidities in Gout at ACR 2020.
Roundtable on Gout: What's Hot at ACR 2020 with Gout Faculty
Drs. Michael Pillinger, Naomi Schlesinger and Robert Keenan discuss the hot topics in Gout in a panel discussion at ACR 2020.
Richard Conway RichardPAConway
4 years 11 months ago
Read my #ACR20 article on diet as a mechanism to control gout @rheumnow https://t.co/nEWJqt8eXx
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 11 months ago
Poll results are in! Most would like to wait for a phase III before prescribing MMF with pegloticase in refractory gout. @RheumNow #ACR20 https://t.co/45MpFliDkE
Pipeline Therapies for Urate Lowering: Dr. Michael Pillinger
Dr. Pillinger reviews abstract #0675 and #0690 presented at the 2020 ACR annual meeting.
Richard Conway RichardPAConway
4 years 11 months ago
Dr McCormick presents on causal association between hyperuricaemia and diabetes. Insulin resistance causal for high urate. Target insulin resistance to prevent gout. @rheumnow #ACR20 Abstr#1472 https://t.co/OSr3ktIXSS
Mrinalini Dey DrMiniDey
4 years 11 months ago
#Multimorbidity in #RheumaticDisease: Abs#1466:
-Highly prevalent across RA, PsA, gout & OA
-Highest burden in #gout
Important study highlighting need to recognise burden of MM in #rheumatology patients for holistic optimised management.
#ACR20 @RheumNow
https://t.co/esinnHoUME https://t.co/bApXfx7hOU
Poster Hall